Industry Insights

  1. Is It Time To Leave The Biotech Incubator? 6/8/2020

    Kavitha Iyer Rodrigues, founder of Zumutor Biologics, Inc. offers experience-based insight into maximizing the value of incubation time, and knowing when it’s time to spread your wings and step out of the nest.

  2. How Can Contract Organizations Bridge The Talent Gap In Biopharma? 4/7/2022

    Instrument vendors can play a critical role in decreasing the training timeline for new and even existing staff at a contract organization.

  3. Do We Need Comparative Clinical Efficacy Testing For Biosimilars? 4/7/2020

    This article examines the nature of comparative efficacy testing and suggests that these studies may be providing misleading evidence of safety and efficacy of biosimilars and should be replaced with more objective pharmacokinetic studies.

  4. April 2025 — CDMO Opportunities And Threats Report 5/8/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

  5. Can Molecular Modeling Overcome The Limitations Of Drug Discovery AI? 7/11/2022

    In small molecule drug development's search for computational approaches to assist drug discovery, there are limitations to using artificial intelligence (AI), the largest one being AI's data problem. How can molecular modeling overcome AI's limitations for more successful small molecule drug discovery?

  6. The Patent Cliff Looms – Design Your Biosimilar Approach Accordingly 3/3/2025

    In your pursuit of developing a high-quality biosimilar, think strategically. Consider what type of biologic your team’s expertise can support and which is needed most in your target market.

  7. Developing A Therapeutic Platform To Enable Immunotherapy For Liver Tumors 12/22/2020

    The deep and durable responses achieved in certain indications with immunotherapies have largely eluded those patients suffering with liver tumors.

  8. Renovating An Existing Biotech Plant To Accommodate A Higher-Titer Product 1/11/2018

    Today, a wide spectrum of plants are moving into their next generation of production of monoclonal antibodies (mAbs) and other therapeutic expressions. This new higher titer changes the way we look at both the process and the facility.

  9. Biotech's Plastic Problem Meets Its Match 8/8/2025

    Explore how a partnership with UW–Madison and Genentech developed a breakthrough recycling technology that is poised to reshape single-use bioprocessing sustainability.

  10. Latin America Offers Welcoming Entry Market Amid Tighter EU Regulations 6/12/2019

    In the past, regulatory requirements that were laxer than U.S. rules made the EU almost a no-brainer as an entry market for many medtechs. However, the advent of the MDR and IVDR has tightened EU regulations and added implementation challenges. Are Latin American markets the answer?